Abstract
Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumor with an increasing incidence linked to asbestos exposure, its main etiological factor. MPM is also a very important issue because patients have usually a short survival (median <12 months) despite current treatments. Moreover an optimal treatment for MPM is not defined yet, even if ERS/ESTS experts recently provided clear and up-to-date guidelines on MPM management. These guidelines on chemotherapy and radiotherapy for mesothelioma, as well as new therapeutic developments, are presented in this chapter.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Asbestos / toxicity
-
Combined Modality Therapy
-
Gefitinib
-
Genetic Therapy
-
Histone Deacetylase Inhibitors / therapeutic use
-
Humans
-
Immunologic Factors / therapeutic use
-
Mesothelioma / chemically induced
-
Mesothelioma / radiotherapy
-
Mesothelioma / therapy*
-
Pleural Neoplasms / chemically induced
-
Pleural Neoplasms / radiotherapy
-
Pleural Neoplasms / therapy*
-
Quinazolines / therapeutic use
-
Ribonucleases / therapeutic use
-
Thalidomide / therapeutic use
Substances
-
Antineoplastic Agents
-
Histone Deacetylase Inhibitors
-
Immunologic Factors
-
Quinazolines
-
Asbestos
-
Thalidomide
-
Ribonucleases
-
Gefitinib
-
ranpirnase